American Association for Cancer Research

Press Releases: 2012

Young Women With Breast Cancer Were More Likely Than Older Women to Respond to Neoadjuvant Chemotherapy


December 6, 2012

Bookmark and Share

  • Finding was confined to those with triple-negative and luminal-type breast cancer.
  • Better outcomes seen for young women with luminal A-like tumors who achieved a pathological complete response compared with those who did not.
  • Neoadjuvant chemotherapy needed for young women, even those with HR-positive, HER2-negative disease.
SAN ANTONIO — Women with breast cancer aged 35 or younger were more likely than older women to achieve a pathological complete response after neoadjuvant chemotherapy, according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 4-8.

“Young women with breast cancer are rare, and some data indicate that their prognosis is worse than it is for older women,” said Sibylle Loibl, M.D., Ph.D., an associate professor at the University of Frankfurt in Germany. “This is not only because their tumors tend to be more aggressive, but because breast tumors that arise in women who are young seem to be a special biological entity.”

Loibl and colleagues evaluated data from eight German studies that included 8,949 women with operable or locally advanced, nonmetastatic breast cancer who were treated with neoadjuvant chemotherapy. The researchers compared pathological complete response and disease-free survival for the subgroup of 704 women aged 35 or younger to those of older women. The subgroup of younger women included a greater proportion of triple-negative breast cancer cases and a smaller proportion of luminal A-type breast cancer cases than in the group of women aged older than 35 (26 percent versus 19 percent and 21 percent versus 27 percent for triple-negative and luminal A-type, respectively).

The pathological complete response rate was significantly higher in very young women — 23.6 percent compared with 15.7 percent among older women. Through further analysis, the researchers found this difference was isolated to women with triple-negative breast cancer and luminal-like breast cancer.

They found no difference in disease-free survival according to age among those patients who achieved a pathological complete response. However, disease-free survival was significantly worse among young women who did not achieve a pathological complete response.

In addition, tumor biology seemed to play an important role, especially in young women, for predicting pathological complete response and survival, according to Loibl. Age, but not pathological complete response, predicted disease-free survival in women with luminal A-type cancer. However, the worst disease-free survival rate was among women with this type of cancer who were younger than 35 and did not achieve a pathological complete response. The best disease-free survival rate was among women younger than 35 who did achieve a pathological complete response.

“The most surprising finding was that young women with a luminal-type tumor — hormone receptor-positive and HER2-negative — who achieved a pathological complete response had a better survival rate than the patients with nonpathological complete response,” Loibl said. “This is not true for other age groups, which indicates that breast cancer in the young — even when a luminal-type breast cancer — is chemosensitive.”

# # #

The mission of the 2012 CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for patients with breast cancer. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor and the AACR’s scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. For more information about the symposium, please visit www.sabcs.org.  

Media Contact:
Jeremy Moore
(215) 446-7109
Jeremy.Moore@aacr.org
In San Antonio, Dec. 4-8:
(210) 582-7035